TickerKhojPharmaceuticals · Pharmaceuticals: Major · NSE: GLAND · data 2026-11-02
Gland Pharma Ltd.
In plain words
Price: 2.4% below its 52-week high of ₹3,171.
Delivery: 57.3% of traded shares were kept for delivery over the last 10 sessions, against 53.7% over the last 60.
Latest results: a net profit of ₹317 cr for the quarter ended Jun 2026 (+47.1% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹6,725 cr |
| Net profit (last 12 months) | ₹1,129 cr |
| Sales growth, 3 years (yearly) | 21.1% |
| Profit growth, 3 years (yearly) | 9.6% |
At a glance
Promoters 45.8% (-6.1 pts in a year), pledged 0.0%, institutions 43.6%.
P/E 45.2, dividend yield 0.7%. Price relative to earnings and book value (low is cheaper, not better).
ROE 10.5%, ROCE 12.0%, operating margin 19.6%: how much profit it earns on the money it uses.
Debt/equity 0.03, Profit growth 9.6% and sales growth 21.1% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Virtually debt-free (debt/equity 0.1 or less).
- Promoters cut their holding by 6.1 points in a year.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q1 FY27)
GLAND Q1 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹1,800.27 crore, up 19.6% YoY and up 3.3% QoQ.
Net profit was ₹316.96 crore, up 47.1% YoY and down 13.6% QoQ.
Operating margin was 27.2% (24.4% a year ago).
EPS was ₹19.23, up 47% YoY and down 13.6% QoQ.
GLAND के Q1 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹1,800.27 करोड़; पिछले साल की तुलना में 19.6% की बढ़त, पिछली तिमाही की तुलना में 3.3% की बढ़त।
शुद्ध मुनाफ़ा: ₹316.96 करोड़; पिछले साल की तुलना में 47.1% की बढ़त, पिछली तिमाही की तुलना में 13.6% की गिरावट।
ऑपरेटिंग मार्जिन: 27.2% (एक साल पहले 24.4%)।
EPS: ₹19.23; पिछले साल की तुलना में 47% की बढ़त, पिछली तिमाही की तुलना में 13.6% की गिरावट।
GLANDના Q1 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹1,800.27 કરોડ; ગયા વર્ષની સરખામણીએ 19.6% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 3.3% વધારો.
ચોખ્ખો નફો: ₹316.96 કરોડ; ગયા વર્ષની સરખામણીએ 47.1% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 13.6% ઘટાડો.
ઓપરેટિંગ માર્જિન: 27.2% (એક વર્ષ પહેલાં 24.4%).
EPS: ₹19.23; ગયા વર્ષની સરખામણીએ 47% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 13.6% ઘટાડો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
45/100 · Building over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 14/30: Delivery 55.2% over the last 20 sessions vs 41.0% in the 40 before (1.35x); shares delivered per day 0.72x usual; 1 delivery-spike day (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 13/15: 34 schemes hold it, about ₹5,307 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 13/15: Verdict "Sustained", sustained score 61/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Deal ● Dividend ● Results
- 17 Sept 26Deal Block deal: BOFA SECURITIES EUROPE SA bought ₹42.4 cr (net ₹0 cr) +4.8% next session
- 11 Aug 26Dividend Dividend ₹20 (ex-date) +8.4% next session
- 10 Aug 26Results Q1 FY27 results: profit +47.1% YoY +12.4% next session
- 15 May 26Results Q4 FY26 results: profit +96.6% YoY +13.6% next session
- 28 Jan 26Results Q3 FY26 results: profit +27.7% YoY +7.4% next session
- 3 Nov 25Results Q2 FY26 results: profit +12.3% YoY -0.9% next session
- 14 Aug 25Dividend Dividend ₹18 (ex-date) +1.2% next session
- 5 Aug 25Results Q1 FY26 results: profit +49.9% YoY -1.3% next session
- 20 May 25Results Q4 FY25 results: profit −3.1% YoY +5.9% next session
- 3 Feb 25Results Q3 FY25 results: profit +6.7% YoY -4.7% next session
- 4 Nov 24Results Q2 FY25 results: profit −15.7% YoY +11.3% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹1,800 cr | ₹317 cr | +47.1% | 27.2% | 19.23 |
| Mar 2026 | ₹1,743 cr | ₹367 cr | +96.6% | 29.4% | 22.26 |
| Dec 2025 | ₹1,695 cr | ₹261 cr | +27.7% | 25.7% | 15.87 |
| Sept 2025 | ₹1,487 cr | ₹184 cr | +12.3% | 21.1% | 11.15 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 45.75% | 51.77% | 51.83% | 51.83% |
| Foreign institutions (FII) | 10.36% | 8.74% | 7.30% | 7.58% |
| Domestic institutions (DII) | 33.21% | 30.44% | 33.35% | 32.98% |
| Mutual funds | 29.52% | 28.23% | 31.78% | 31.42% |
| Retail investors | 4.02% | 2.89% | 1.93% | 1.97% |
| Number of shareholders | 1,25,667 | 1,08,266 | 91,500 | 94,578 |
Common questions
What was Gland Pharma Ltd.'s latest quarterly profit?
Gland Pharma Ltd. reported a net profit of ₹317 cr for the quarter ended Jun 2026 (+47.1% on the same quarter a year earlier), on revenue of ₹1,800 cr.
How much do promoters hold in Gland Pharma Ltd.?
Promoters held 45.75% of Gland Pharma Ltd. at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Gland Pharma Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0.03, which is very low.
What is Gland Pharma Ltd.'s P/E ratio?
About 45.2, based on the last 12 months' earnings and a price of ₹3,096.1 (data 2026-11-02).
What is the 52-week high and low of Gland Pharma Ltd.?
The 52-week high is ₹3,171 and the 52-week low is ₹1,573.6.
Mutual funds holding Gland Pharma Ltd.
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 34 schemes holding about ₹5,307 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| SBI Large and Midcap Fund | SBI Mutual Fund | 2.28% | ₹923 cr |
| Nippon India Growth Mid Cap Fund | Nippon India Mutual Fund | 1.62% | ₹813 cr |
| NIPPON INDIA SMALL CAP FUND | Nippon India Mutual Fund | 0.66% | ₹534 cr |
| Mirae Asset Large & Midcap Fund | Mirae Asset Mutual Fund | 1.15% | ₹493 cr |
| SBI Contra Fund | SBI Mutual Fund | 0.72% | ₹325 cr |
| Mirae Asset Midcap Fund | Mirae Asset Mutual Fund | 1.54% | ₹301 cr |
| Nippon India ELSS Tax Saver Fund | Nippon India Mutual Fund | 2.06% | ₹290 cr |
| NIPPON INDIA PHARMA FUND | Nippon India Mutual Fund | 2.53% | ₹232 cr |
| Mirae Asset Large Cap Fund | Mirae Asset Mutual Fund | 0.52% | ₹185 cr |
| SBI Healthcare Opportunities Fund | SBI Mutual Fund | 2.96% | ₹174 cr |
| Mirae Asset Small Cap Fund | Mirae Asset Mutual Fund | 1.85% | ₹108 cr |
| Mirae Asset Multicap Fund | Mirae Asset Mutual Fund | 1.99% | ₹107 cr |
| ADITYA BIRLA SUN LIFE MNC FUND | Aditya Birla Sun Life Mutual Fund | 3.40% | ₹103 cr |
| Mirae Asset Healthcare Fund | Mirae Asset Mutual Fund | 2.69% | ₹94 cr |
| ADITYA BIRLA SUN LIFE SMALL CAP FUND | Aditya Birla Sun Life Mutual Fund | 1.47% | ₹90 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Gland Pharma Ltd. | ₹3,096.1 | ₹51,112 cr | 45.2 | — | 10.5% | 12% | 0.03 | +61.3% |
| Alkem Laboratories Ltd. | ₹5,088.5 | ₹61,277 cr | 28.2 | — | 17.8% | 17.8% | 0.15 | -7.9% |
| Biocon Limited | ₹354.95 | ₹57,310 cr | 105.6 | 1.6 | 1.4% | 3.5% | 0.45 | -6.1% |
| Abbott India Limited | ₹25,665 | ₹54,384 cr | 33.8 | — | 34.5% | 39.1% | 0.04 | -13.4% |
| IPCA Laboratories Limited | ₹1,956.6 | ₹48,898 cr | 37.9 | — | 15.2% | 16.3% | 0.1 | +51.0% |
| Ajanta Pharma Limited | ₹3,438.9 | ₹43,891 cr | 34.1 | 8.8 | 25.4% | 30% | 0.06 | +39.3% |
Compare GLAND with ALKEM in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open GLAND in TickerKhoj →